Adopting 3-Year Screening Intervals for Sight-Threatening Retinal Vascular Lesions in Type 2 Diabetic Subjects Without Retinopathy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To report the incidence of sight-threatening vascular lesions in type 2 diabetic subjects without retinopathy after adopting a 3-year interval screening program. RESEARCH DESIGN AND METHODS: In all, 1,691 type 2 diabetic subjects with no detectable retinopathy in two 50° red-free fundus photographs were scheduled for follow-up with photography 3 years later. Age at diabetes diagnosis was 60 ± 12 years, and known duration of diabetes was 6 ± 6 years. Treatment consisted of diet only (26%), oral agents (54%), and oral agents and/or insulin (20%). Glycated hemoglobin A1c was 6.4 ± 1.5%. RESULTS: Of the 1,322 subjects available for follow-up, 73% were still without retinopathy after 3 years, and 28% had developed mild or moderate retinopathy, but none developed severe nonproliferative or proliferative retinopathy. Macular edema requiring laser coagulation occurred in only one eye. CONCLUSIONS: Three-year retinal screening intervals can be recommended in subjects with mild type 2 diabetes and no retinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Artificial intelligence approaches to screening for diabetic retinopathy have progressed to the point of utility and cost-effectiveness.508–513”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [513]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wilkinson, C. P., Ferris, F. L., Klein, R. E., Lee, P. P., Agardh, C. D., Davis, M., Dills, D., Kampik, A., Pararajasegaram, R., & Verdaguer, J. T. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00475-5 · Cited by 3,743
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Screening and prevention of diabetic blindness
Stefánsson, E., Bek, T., Porta, M., Larsen, N., Kristinsson, J. K., & Agardh, E. (2000) · Acta Ophthalmologica Scandinavica · doi:10.1034/j.1600-0420.2000.078004374.x · Cited by 292 · cited 1×
“In Sweden, biennial screening examinations have long been standard for subjects without retinopathy (1).”
BackgroundSelf-citationYounis, N., Broadbent, D. M., Vora, J. P., & Harding, S. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12267-2 · Cited by 289
Diabetic retinopathy screening: a systematic review of the economic evidence
Jones, S., & Edwards, R. T. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02870.x · Cited by 265 · cited 1×
“CONCLUSIONS—Screening for diabetic retinopathy is highly important for the individual in years of saved vision and for society with respect to costs associated with blindness and visual impairment (4).”
BackgroundKollias, A. N., & Ulbig, M. W. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0075 · Cited by 253
Scanlon, P. H. (2008) · Journal of Medical Screening · doi:10.1258/jms.2008.008015 · Cited by 132
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s · cited 1×
“The World Health Organization has lowered the limits for what are considered to be normal reference ranges for blood and plasma glucose levels (9), which has led to the earlier diagnosis of diabetes and has probably also lowered the risk of sightthreatening retinopathy.”
Background
Research works printed but not linked: 1
- Diabetic Retinopathy Screening Implementation Group, 2003, Diabetic retinopathy screening services in Scotland: recommendations for implementations, 69
Cited by
Items 101–120 of 120
Cribado de patología oftalmológica
Bravo, L. J. N., & García, R. A. A. (2019) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2018.10.011 · Cited by 2
Romero‐Aroca, P., Baget‐Bernaldiz, M., Navarro-Gil, R., Feliu, A., Maarof, N., Moreno, A., Cristiano, J., & Valls, A. (2022) · Clinical ophthalmology · doi:10.2147/opth.s351790 · Cited by 2
Shinzato, Y., Nakayama, Y., Okamoto, S., Millman, J. F., Uema, T., Honma, K.-I., Tamaki, A., Uehara, M., Teruya, T., Yabiku, T., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00724-7 · Cited by 1
“Incidence of DR was assessed in diabetic subjects with NDR at the baseline by worsening in stage (i.e., from NDR to NPDR or PDR), and progression of DR in diabetic subjects with NPDR at the baseline was defined as a worsening in stage (i.e., from NPDR to PDR) [30, 31].”
Pitt, M., Olvera‐Barrios, A., Anderson, J., Bolter, L., Chambers, R., Warwick, A., Mann, S. S., Webster, L., Fajtl, J., Barman, S. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06379-6 · Cited by 1
“Other countries have implemented extended diabetic eye screening intervals among people perceived to be at ‘low risk’ [13, 32], but the present study provides strong evidence that such approaches may not be equitable, particularly in sociodemographically diverse populations, and should be monitored…”
Retinopathy, Neuropathy, and Foot Care
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch19 · Cited by 1
Byberg, S., Vistisen, D., Jørgensen, M. E., Díaz, L. J., Valerius, M., Hajari, J. N., & Lund‐Andersen, H. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14590 · Cited by 1
“‡ Included in the dysregulation variable. e363 the study participants developed treatment requiring DR after three years (Agardh & Tababat-Khani 2011).”
BackgroundBarbaresko, J., Lang, A. S., Szczerba, E., Bächle, C., Beckhaus, J., Schwingshackl, L., Neuenschwander, M., & Schlesinger, S. (2023) · doi:10.2337/figshare.21561987 · Cited by 1
Statistical methods for studying the frequency of monitoring chronic conditions
Oke, J. L., & Oke, J. (2014) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-qrbe64ypr · Cited by 1
Petersen, G. B. (2024) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau715862415 · Cited by 1
Visual impairment, blindness and retinopathy in older Icelanders
Gunnlaugsdóttir, E. (2013) · Skemman
Protocolo sobre manejo de la diabetes mellitus tipo 2
Loiola, P. E., Loiola, P. E., Agirre, A. E., Idarreta, I., Gea, L. B., Baquedano, M. M., Asumendi, P. D., Canibe, I. V., & Etxeandia‐Ikobaltzeta, I. (2015) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2015.04.002
Retinal Complications in Diabetes Mellitus: Importance of Screening and Management
Golubovik, M. (2014) · PRILOZI · doi:10.1515/prilozi-2015-0021
“Respecting the recommendations of the previous studies, first of all of ETDRS, and based on clinical evidence presented in recent studies, together with the conclusions of American Diabetes Assotiation (ADA) and American Academy of Ophthalmology ( AAO) [8, 9, 10, 11, 14], National Health and Medical Research Council (…”
MethodOptimising the cost-effectiveness of risk-based screening for diabetic retinopathy
Sampson, C. (2020) · Nottingham ePrints (University of Nottingham)
Renard, L. (2012) · theses.fr (ABES) · doi:10.70675/8addae69z0b0fz4f69zb3fbzc44b2f89021a
Wang, A. (2014) · doi:10.1186/isrctn87561257
Biennial diabetic eye screening: unveiling ethnic and age-related disparities in delayed diagnosis
Raman, R., & Ravichandran, J. S. (2024) · Evidence-Based Nursing · doi:10.1136/ebnurs-2023-103922
Outcomes of PCI of all comers: the experience of a Kuwaiti independent healthcare institution
Mudawi, T. O., Alenezi, W., Amin, A., Besada, D., Aly, A., Fathi, A., Khdair, D. A., & Alanbaei, M. (2024) · British Journal of Cardiology · doi:10.5837/bjc.2024.016
Aravindhan, A., Fenwick, E., Chan, A. W. D., Man, R. E. K., Tan, N. C., Wong, W. T., Soo, W. F., Lim, S. W., Wee, S. Y.-M., Sabanayagam, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25405956
Aravindhan, A., Fenwick, E., Chan, A. W. D., Man, R. E. K., Tan, N. C., Wong, W. T., Soo, W. F., Lim, S. W., Wee, S. Y.-M., Sabanayagam, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25406100
日本人2型糖尿病患者における糖尿病性網膜症の発症あるいは増悪に関連する因子の性差に関する後方視的探索研究
Nakayama, Y., & 中山, 良. (2021) · Institutional Repositories DataBase (IRDB)
Metadata
- Authors
- Agardh, E., & Tababat-Khani, P.
- Affiliations
- Lund University (SE)
- Department of Clinical Sciences Malmö, Ophthalmology, Skåne University Hospital Malmö, Lund University, Malmö, Sweden.
- Corresponding author
- Agardh, Elisabet
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-05-20
- Volume
- 34
- Issue
- 6
- Pages
- 1318-1319
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3114331
- OpenAlex
- W2120206300
- Cited by
- 113
- References
- 8
- Citations by year
- 2025: 6 · 2024: 11 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 13 · 2019: 9 · 2018: 2 · 2017: 8 · 2016: 7 · 2015: 11 · 2014: 8 · 2013: 10 · 2012: 8
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Ögonfonden
- Stiftelsen för Synskadade i f.d. Malmöhus län
- Lunds Universitet
- Svenska Läkaresällskapet
- Skånes universitetssjukhus
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetic retinopathy, retinal vascular lesions, macular edema, retinopathy progression, HbA1c
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Humans, Macular Edema, Middle Aged, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
